miR-34a also targets SIRT1, which is pharmacologically beneficial for obesity disorders since it has been shown that SIRT1 activity increases oxidative metabolism as well as mitochondrial function (Fig. 1) [93, 95]. This evidence concerns the gene SIRT1 and obesity due to melanocortin 4 receptor deficiency.